Quick Answer
Nuvation Bio Inc. reported Operating Income Loss of -$213.06 million for the year ending 2025.
- Nuvation Bio Inc. showed an increase of +64.0% in Operating Income Loss from 2024 to 2025.
- This data is from Nuvation Bio Inc.'s annual report (Form 10-K), filed with the SEC on March 2, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$9.22 million | Q2 2020: -$9.02 million | Q3 2020: -$11.55 million | Q1 2021: -$20.48 million | Q2 2021: -$20.43 million | Q3 2021: -$22.79 million | Q1 2022: -$28.19 million | Q2 2022: -$37.87 million | Q3 2022: -$29.34 million | Q1 2023: -$26.52 million | Q2 2023: -$26.13 million | Q3 2023: -$26.34 million | Q1 2024: -$20.20 million | Q2 2024: -$470.39 million | Q3 2024: -$48.10 million | Q1 2025: -$59.00 million | Q2 2025: -$63.59 million | Q3 2025: -$56.43 million.
- Over the full 6 years of available data (2020 to 2025), Nuvation Bio Inc.'s Operating Income Loss has declined by 389.2%.
- Historical annual values: Fiscal year 2025: -$213.06 million | Fiscal year 2024: -$592.63 million | Fiscal year 2023: -$99.82 million | Fiscal year 2022: -$119.73 million | Fiscal year 2021: -$93.32 million | Fiscal year 2020: -$43.55 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: